Evidence map›Paper›PMID 19058005›Full record

ArticleDigestive diseases and sciences2009

Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?

Gregory Kouraklis, Iraklis E Katsoulis, Stamatios Theocharis, Gerasimos Tsourouflis, Nikos Xipolitas, Andromahi Glinavou, Chrysa Sioka, Alkiviadis Kostakis

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Genes · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Pathogenetic mechanisms in gastric cancer.World journal of gastroenterology · 2014
    Review
  14. Article
  15. Article
  16. The overexpression of AP-4 as a prognostic indicator for gastric carcinoma.Medical oncology (Northwood, London, England) · 2012
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Gregory Kouraklis2nd Department of Propedeutic Surgery, Medical School University of Athens, Athens, Greece. gkouraklis@hotmail.com
Iraklis E Katsoulis
Stamatios Theocharis
Gerasimos Tsourouflis
Nikos Xipolitas
Andromahi Glinavou
Chrysa Sioka
Alkiviadis Kostakis
National and Kapodistrian University of Athens · GRAthens State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCyclin E is a protein that plays a key role in the G1 --> S transition of the normal cell cycle. The product of retinoblastoma gene (pRb) is the master regulator of entry into the cell cycle and p21 protein is a cyclin-dependent kinase inhibitor that disturbs the progression through the cell cycle. The expression of these proteins, among many others, is being deregulated in tumorogenesis. The aim of this study was to investigate whether cyclin E, pRb, and p21 can be used as prognostic indicators in gastric cancer. MATERIAL AND

methodsFifty-six patients with gastric adenocarcinoma, who underwent curative resection, constituted the group of our study. The immunohistochemical expression of cyclin E, pRb, and p21 proteins was examined and correlated with clinical-pathological parameters and survival.

resultsPositive cyclin E immunostaining was observed in 23 tumors (41.1%). It was associated with intestinal Lauren classification (P=0.003), nodal infiltration (P=0.0025), size of the tumor >5 cm (P=0.032), and lymphatic (P=0.042) and vascular invasion (P= 0.0029). Nevertheless, the survival of patients with positive cyclin E tumors was not significantly shorter than that of negative patients. Positive pRb immunostaining was found in 24 (42.9%) cases and it was associated with the absence of Helicobacter pylori (P=0.044), whereas positive p21 immunostaining was found in 21 tumors (37.5%) and it was associated with less depth of gastric wall infiltration (P=0.001), the absence of lymphatic (P=0.019) and vascular infiltration (P=0.024), and the absence of liver metastasis (P=0.044). Cyclin E expression was associated with pRb expression (P=0.023), but was correlated inversely with p21 expression (P=0.009). The survival of patients with pRb-positive tumors and the survival of patients with p21-positive tumors were significantly longer than that of negative patients (P= 0.0044 and P<0.001, respectively).

conclusionThe expression of cyclin E could not predict the survival in this series of patients with gastric cancer, whereas the expression of pRb and p21 was associated with a favorable prognosis.

Indexed as

GastrectomyAdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p21Cyclin EFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedOncogene ProteinsPhosphorylationBiomarkers, TumorCCNE1 protein, humanCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Cyclin EOncogene ProteinsRetinoblastoma Protein

Identifiers

PMID19058005
OpenAlexW1991832657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.